This document provides an overview of Swift Biosciences' product training series for their APAC distributors on using Swift products for cancer studies. It summarizes different Swift library preparation and sequencing kits that can be used for various cancer applications, including genomic sequencing, RNA sequencing, amplicon panels, hybridization capture, and DNA methylation. The document also reviews types of mutations found in cancer, considerations for cancer clinical workflows, and provides an example of using Swift's 2S Turbo kit for targeted sequencing of formalin-fixed, paraffin-embedded tissue samples.
Sensitive and Reliable Variant Detection From Challenging SamplesQIAGEN
The QIAseq Ultralow Input Library Kit enables sensitive and reliable variant detection from challenging clinical samples through an optimized workflow:
- The kit utilizes optimized enzymes and buffers to construct high-quality sequencing libraries from as little as 10 pg DNA input, with high conversion rates and uniform coverage regardless of GC content.
- When used with hybridization-based target enrichment, it allows reliable variant detection from sample types with limited or low-quality DNA, such as laser-capture microdissection samples, formalin-fixed samples, and cell-free DNA.
- Testing demonstrated high sensitivity (>90%) and precision (>99.5%) for variant calling from just 1 ng DNA input using whole-genome or
Fast and Efficient Post-Bisulfite-Seq Library Construction with QIAseq Ultral...QIAGEN
The document describes a new method called post-bisulfite next-generation sequencing library construction (PBLC) for whole genome bisulfite sequencing (WGBS) that overcomes challenges with traditional WGBS workflows. PBLC involves bisulfite treatment before library preparation, which fragments the DNA so no additional fragmentation is needed. This reduces workflow time and enables epigenomic studies from lower DNA inputs. Comparison studies show PBLC produces higher library yields than traditional WGBS and comparable sequencing results, making it a more efficient and sensitive method for WGBS.
Innovative NGS Library Construction TechnologyQIAGEN
Next-generation sequencing (NGS) is a driving force for numerous new and exciting applications, including cancer research, stem cell research, metagenomics, population genetics, medical research and single cell analysis. While NGS technology is continuously improving, library preparation remains one of the biggest bottlenecks in the NGS workflow and includes several time-consuming steps that can result in considerable sample loss and the potential to introduce handling errors. Moreover, conducting single-cell genomic analysis using NGS methods has traditionally been challenging since the amount of genomic DNA present in a single cell is very limited.
The QIAseq NGS Portfolio for Cancer Research: Sample-to-Insight for AllQIAGEN
The document summarizes the QIAseq NGS portfolio from QIAGEN for cancer research and other applications. It describes several QIAseq kits that provide streamlined workflows for targeted DNA sequencing, whole genome sequencing, single-cell sequencing, cell-free DNA sequencing, and single-cell RNA sequencing. The kits are shown to provide high library conversion rates even from low input DNA amounts down to 10 pg, with uniform coverage and low GC bias.
This document summarizes QIAGEN's products for sample preparation, targeted sequencing, and single-cell analysis across various areas of biomedical research including liquid biopsy, circulating tumor cells, and gene expression profiling. Key products mentioned are the QIAseq cfDNA All-in-One Kits for streamlined library preparation from plasma/serum, QIAseq Targeted DNA/RNA Panels for digital sequencing of genomic regions or genes, and QIAseq FX Single Cell DNA/RNA Library Kits for cell-to-library workflows from isolated single cells.
Digital RNAseq Technology Introduction: Digital RNAseq Webinar Part 1QIAGEN
QIAseq RNA is a revolutionary turnkey solution for digital gene expression analysis by NGS. From 10 genes to 1000, from one sample to 100, QIAseq RNA delivers precise results on both ION and Illumina sequencing platforms. The data from QIAseq RNA is directly comparable to expression analysis derived from whole transcriptome sequencing or by qRTPCR, only better, cheaper, faster, and more flexible. This webinar will describe the principles of digital expression analysis by NGS, and review the features and benefits of the QIAseq system, options available, and the integrated data analysis package.
The document describes the ABRF Next Generation Sequencing Study which aims to produce reference data sets to establish baseline performance of sequencing platforms and methods. Phase I focused on RNA-Seq and produced major conclusions about intraplatform and interplatform concordance. Phase II will focus on DNA sequencing including performance using different platforms/protocols, damaged DNA, small genomes, and oncogenic mutations. Samples and sequencing plans are described for three projects. The study is a collaboration between ABRF and Genome in a Bottle to generate standardized reference data.
Digital DNA-seq Technology: Targeted Enrichment for Cancer ResearchQIAGEN
Targeted DNA sequencing has become a powerful approach by achieving high coverage of the region of interest while keeping the cost of sequencing and complexity of data interpretation manageable. However, existing PCR-based target enrichment approaches introduce errors due to PCR amplification bias and artifacts, which significantly affects quantification accuracy and limit the ability to confidently detect low-frequency DNA variants. This webinar introduces a new digital sequencing approach that is based on the use of unique molecular indices (UMIs) - QIAseq Targeted DNA Panels. With UMIs, each unique DNA molecule is barcoded before any amplification takes place to correct for PCR errors. Detailed workflow and applications in cancer research will be presented. Join us and learn about this exciting novel digital DNAseq technology
Sensitive and Reliable Variant Detection From Challenging SamplesQIAGEN
The QIAseq Ultralow Input Library Kit enables sensitive and reliable variant detection from challenging clinical samples through an optimized workflow:
- The kit utilizes optimized enzymes and buffers to construct high-quality sequencing libraries from as little as 10 pg DNA input, with high conversion rates and uniform coverage regardless of GC content.
- When used with hybridization-based target enrichment, it allows reliable variant detection from sample types with limited or low-quality DNA, such as laser-capture microdissection samples, formalin-fixed samples, and cell-free DNA.
- Testing demonstrated high sensitivity (>90%) and precision (>99.5%) for variant calling from just 1 ng DNA input using whole-genome or
Fast and Efficient Post-Bisulfite-Seq Library Construction with QIAseq Ultral...QIAGEN
The document describes a new method called post-bisulfite next-generation sequencing library construction (PBLC) for whole genome bisulfite sequencing (WGBS) that overcomes challenges with traditional WGBS workflows. PBLC involves bisulfite treatment before library preparation, which fragments the DNA so no additional fragmentation is needed. This reduces workflow time and enables epigenomic studies from lower DNA inputs. Comparison studies show PBLC produces higher library yields than traditional WGBS and comparable sequencing results, making it a more efficient and sensitive method for WGBS.
Innovative NGS Library Construction TechnologyQIAGEN
Next-generation sequencing (NGS) is a driving force for numerous new and exciting applications, including cancer research, stem cell research, metagenomics, population genetics, medical research and single cell analysis. While NGS technology is continuously improving, library preparation remains one of the biggest bottlenecks in the NGS workflow and includes several time-consuming steps that can result in considerable sample loss and the potential to introduce handling errors. Moreover, conducting single-cell genomic analysis using NGS methods has traditionally been challenging since the amount of genomic DNA present in a single cell is very limited.
The QIAseq NGS Portfolio for Cancer Research: Sample-to-Insight for AllQIAGEN
The document summarizes the QIAseq NGS portfolio from QIAGEN for cancer research and other applications. It describes several QIAseq kits that provide streamlined workflows for targeted DNA sequencing, whole genome sequencing, single-cell sequencing, cell-free DNA sequencing, and single-cell RNA sequencing. The kits are shown to provide high library conversion rates even from low input DNA amounts down to 10 pg, with uniform coverage and low GC bias.
This document summarizes QIAGEN's products for sample preparation, targeted sequencing, and single-cell analysis across various areas of biomedical research including liquid biopsy, circulating tumor cells, and gene expression profiling. Key products mentioned are the QIAseq cfDNA All-in-One Kits for streamlined library preparation from plasma/serum, QIAseq Targeted DNA/RNA Panels for digital sequencing of genomic regions or genes, and QIAseq FX Single Cell DNA/RNA Library Kits for cell-to-library workflows from isolated single cells.
Digital RNAseq Technology Introduction: Digital RNAseq Webinar Part 1QIAGEN
QIAseq RNA is a revolutionary turnkey solution for digital gene expression analysis by NGS. From 10 genes to 1000, from one sample to 100, QIAseq RNA delivers precise results on both ION and Illumina sequencing platforms. The data from QIAseq RNA is directly comparable to expression analysis derived from whole transcriptome sequencing or by qRTPCR, only better, cheaper, faster, and more flexible. This webinar will describe the principles of digital expression analysis by NGS, and review the features and benefits of the QIAseq system, options available, and the integrated data analysis package.
The document describes the ABRF Next Generation Sequencing Study which aims to produce reference data sets to establish baseline performance of sequencing platforms and methods. Phase I focused on RNA-Seq and produced major conclusions about intraplatform and interplatform concordance. Phase II will focus on DNA sequencing including performance using different platforms/protocols, damaged DNA, small genomes, and oncogenic mutations. Samples and sequencing plans are described for three projects. The study is a collaboration between ABRF and Genome in a Bottle to generate standardized reference data.
Digital DNA-seq Technology: Targeted Enrichment for Cancer ResearchQIAGEN
Targeted DNA sequencing has become a powerful approach by achieving high coverage of the region of interest while keeping the cost of sequencing and complexity of data interpretation manageable. However, existing PCR-based target enrichment approaches introduce errors due to PCR amplification bias and artifacts, which significantly affects quantification accuracy and limit the ability to confidently detect low-frequency DNA variants. This webinar introduces a new digital sequencing approach that is based on the use of unique molecular indices (UMIs) - QIAseq Targeted DNA Panels. With UMIs, each unique DNA molecule is barcoded before any amplification takes place to correct for PCR errors. Detailed workflow and applications in cancer research will be presented. Join us and learn about this exciting novel digital DNAseq technology
Analyzing Fusion Genes Using Next-Generation SequencingQIAGEN
Fusion genes are hybrid genes formed by the fusion of two separate genes. Translocation, interstitial deletion and chromosomal inversions are some of the genetic events that can lead to the formation of fusion genes. The occurrence of fusion genes and its implications in cancer have already been known, but the emergence of NGS technology – especially RNA sequencing – offers the potential to detect novel gene fusions. You can learn more about fusion genes and applying NGS to detect them at our upcoming webinar, presented by Raed Samara, Ph.D., QIAGEN’s Global Product Manager for NGS technologies.
In this webinar, Dr. Raed Samara will cover:
1. Fusion genes: what they are and a historical perspective
2. Fusion gene detection: the current status
3. RNA sequencing vs. digital RNA sequencing
4. How to detect and accurately quantify novel fusion genes in your sample
QIAseq Targeted DNA, RNA and Fusion Gene PanelsQIAGEN
Tumor heterogeneity has been known for a while but quantifying heterogeneity is still a challenge. NGS is the method of choice in the analysis of tumor heterogeneity, however, there are some inherent challenges associated with it. These include false positives, gaps in the gene due to overrepresentation and incomplete representation of low-frequency transcripts – all contributing to an inaccurate picture. Conventional library prep strategies for NGS are based on PCR, which introduces sequence-based bias and amplification noise, leading to these inaccuracies. In this webinar, we will cover
1. Principles of UMI and the new QIAseq product porfolio
2. How UMI along with SPE (single primer extension) allows for increased uniformity across difficult-to-sequence regions, removal of library construction bias, improved data analysis and sequencing optimization
3. How data generated from using UMI and SPE is directly comparable to analysis derived from whole transcriptome and exome sequencing
4. Application of UMI and SPE in the discovery of novel gene fusions and in the analysis of gene expression and genetic variation
Semi Automated Low-throughput Workflow for Microbial Analyses of Human StoolQIAGEN
The gut microbiota composition changes dramatically throughout aging and disease. A healthy gut microbiota is typically characterized by large bacterial taxonomic diversity and functional capacity, whereas frailty and aging are associated with loss of diversity and expansion of more pathogenic bacterial species. However, in order to accurately profile changes in microbial communities, the reproducible isolation of high-quality DNA is an important step. Automation enables reliable and reproducible isolation of DNA of superior quality, which can be used directly for downstream sequencing applications.
This webinar focuses on the development of a semi-automated workflow to profile the gut microbiota of young and old individuals and identify changes in bacterial composition and function that occur with age. This workflow will help to simplify and streamline the DNA extraction process for samples with high inhibitor content and subsequent microbial community analyses.
Achieve Complete Coverage of the SARS-CoV-2 GenomeCamille Cappello
Utilize multiple overlapping amplicons in a single tube, using a rapid, 2-hour workflow to prepare ready-to-sequence libraries. The PCR1+PCR2 workflow generates robust libraries even from low input quantities of DNA that may be subsequently quantified and normalized with conventional methods such as Qubit® or Agilent Bioanalyzer, or optionally using the included Swift Normalase reagents.
Provides coverage of >99% of the SARS-CoV-2 genome from limited viral titers
Application Note: A Simple One-Step Library Prep Method To Enable AmpliSeq Pa...QIAGEN
Targeted amplicon sequencing is a cost-effective, convenient and rapid method for variant detection. This application note outlines a straightforward workflow that uses the QIAseq 1-Step Amplicon Library kit to verify AmpliSeq targeted sequencing assays on the Illumina sequencing instruments. By combining end-repair and ligation, the QIAseq 1-Step Amplicon Library Kit offers a fast and efficient 30-minute procedure for the preparation of high-quality, artifact-free Illumina libraries from any PCR amplicons, including AmpliSeq Panels.
With technological breakthroughs in single cell isolation, whole genome amplification (WGA) and NGS library preparation, experiments using single cells are now possible. However, challenges still exist. In particular, methods for the unbiased and complete amplification of a single genome and for the efficient conversion of that amplified DNA into a sequencer-compatible library face several technical limitations including incomplete amplification, the introduction of PCR errors, GC-bias and locus or allelic drop-out. The presentation covers the impact of these factors and how one can mitigate it.
Advanced NGS Library Prep for Challenging SamplesQIAGEN
This document discusses advanced next-generation sequencing (NGS) library preparation methods for challenging samples. It introduces NGS applications using various sample types and sizes. Standard NGS library preparation kits have input requirements that cannot accommodate many sample types and quantities. New techniques optimized for sub-nanogram inputs can construct high-quality libraries from as little as 10 picograms of DNA. These methods show consistent conversion across a wide input range and enable applications like ancient DNA analysis and circulating tumor DNA detection from blood. The document focuses on cell-free DNA library preparation challenges and solutions like the QIAGEN cfDNA library kits.
The transcriptome of a cell is not fixed, but is dynamic, and reflects the function or type of the cell, the cell stage or the cell's response to intrinsic and extrinsic influences, such as signaling or stress factors. Only on a single cell level, can you eliminate the biological noise that is inherent to standard gene expression analysis – providing you the insights needed for a deeper understanding of transcription dynamics. In this presentation we delve into the different steps of RNA seq starting from a single cell.
Next-generation genomics: an integrative approachHong ChangBum
This document summarizes a presentation on next-generation genomics and integrative analysis. It discusses the types of genomic data available from techniques like genome sequencing, RNA sequencing, ChIP-seq, and epigenomics. It explains that integrative analysis can help annotate functional features, infer variant function, and understand gene regulation. Approaches to integration include data reduction, unsupervised clustering, and supervised Bayesian networks. Large-scale datasets can be accessed through browsers, add-ons, and standalone tools to generate novel hypotheses. Future work includes more integrated community resources with search capabilities.
1) The document discusses different whole genome amplification techniques for obtaining DNA from single cells, including PCR-based and PCR-free methods.
2) It provides comparisons of different whole genome amplification kits, finding that QIAGEN's REPLI-g Single Cell Kit has the highest genome coverage, lowest duplication rates, and best performance for detecting copy number variations and single nucleotide variations, making it optimal for single cell sequencing applications.
3) Case studies demonstrate that the REPLI-g Single Cell Kit provides more uniform coverage and significantly fewer sequencing errors compared to the MALBAC method.
Exploring new frontiers with next-generation sequencingQIAGEN
The document describes several next-generation sequencing products from QIAGEN, including the QIAseq Targeted RNA Panels, QIAseq Targeted RNAscan Panels, QIAseq Targeted DNA Panels, QIAseq 1-Step Amplicon Library Kit, QIAseq Ultralow Input Library Kit, and QIAseq cfDNA All-in-One Kit. These products are designed to simplify NGS workflows and provide high-quality libraries from low input samples in order to maximize insights from applications such as single-cell analysis, liquid biopsies, and metagenomics.
Alzheimer’s disease (AD) is a devastating neurodegenerative disease that is genetically complex. Although great progress has been made in identifying fully penetrant mutations in genes that cause early-onset AD, these still represent a very small percentage of AD cases. Large-scale, genome-wide association studies (GWAS) have identified at least 20 additional genetic risk loci for the more common form: late-onset AD. However, the identified SNPs are typically not the actual risk variants, but are in linkage disequilibrium with the presumed causative variants [1].
To help identify causative genetic variants, we have combined highly accurate, long-read sequencing with hybrid-capture technology. In this collaborative webinar*, we present this method and show how combining IDT xGen® Lockdown® Probes with PacBio SMRT® Sequencing allows targeting and sequencing of candidate genes from genomic DNA and corresponding transcripts from cDNA. Using a panel of target capture probes for 35 AD candidate genes, we demonstrate the power of this approach by looking at data for two individuals with AD. Some additional benefits of this method include the ability to leverage long reads, phase heterozygous variants, and link corresponding transcript isoforms to their respective alleles.
Reference: 1. Van Cauwenberghe C, Van Broeckhoven C, Sleegers K. (2016) The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet Med, 18(5):421–430.
* This presentation represents a collaboration between Pacific Biosciences and Integrated DNA Technologies. The individual opinions expressed may not reflect shared opinions of Pacific Biosciences and Integrated DNA Technologies.
The Importance of Quality Control Steps in ExperimentsQIAGEN
From starting material to final results, every analysis workflow is a journey to unlock the biological information within your sample without altering it, and high-quality results are only achieved from high-quality samples.
Within each step, lie challenges directly related to the sample type and analysis technologies, and at each step, there is potential for multiple things to go wrong, jeopardizing your experiments, results and reputation. Therefore, standardizing samples and performing relevant quality control after critical steps is of utmost importance to ensure the quality and reproducibility of results, as well as reliable interpretation.
In this webinar, we will introduce you to the main sample quality parameters and their respective impact on downstream applications, discuss how to monitor them and cover the advantages of automating quality control along complex workflows.
Targeted RNAseq for Gene Expression Using Unique Molecular Indexes (UMIs): In...QIAGEN
Traditional RNA sequencing (RNA-Seq) is a powerful tool for expression profiling, but is hindered by PCR amplification bias and inaccuracy at low expressing genes. QIAseq RNA is a flexible and precise tool developed for mitigating these complications, allowing digital gene expression analysis. This in-depth webinar will cover sample requirements, experimental design, NGS platform-specific challenges and workflow for gene enrichment, library prep and sequencing. The applications of QIASeq RNA Panels in cancer research, stem cell differentiation and elucidating the effects small molecules on signaling pathways will be highlighted.
IDT provides a range of solutions for targeted next generation sequencing. Labs processing hundreds to thousands of samples can create highly uniform, custom panels using xGen® Lockdown Probes. The new xGen Acute Myeloid Leukemia (AML) panel is a predesigned set of Lockdown Probes that captures 260 genes identified by whole genome and exome sequencing of 200 patient samples. The AML panel can be used as stand-alone or customized with additional probes to detect other targets of interest.
New Progress in Pyrosequencing for Automated Quantitative Analysis of Bi- or ...QIAGEN
Pyrosequencing is a highly flexible technology based on sequencing-by-synthesis for the rapid and quantitative analysis of any type of sequence variation. The real-time output delivers high-resolution sequence information, making pyrosequencing highly suitable for applications ranging from biallelic or multiallelic SNP analysis, DNA methylation quantification to complex mutation analysis of multiple sequence variations in a single run.
In this slideeck, we introduce the new PyroMark Q48 Autoprep system which enables fully automated template preparation integrated in the pyrosequencing workflow. In addition, a new Multiple Primer Dispensation (MPD) strategy is presented which allows fully automated dispensation of sequencing primer, offering a seamless workflow from samples to quantitative genotyping results.
This slidedeck focuses on the following topics
• Pyrosequencing technology and workflow in genotyping analysis
• Introduction into the new PyroMark Q48 Autoprep
• MPD strategy for a seamless automated pyrosequencing workflow
Join us and learn how you can apply the new pyrosequencing system and protocol to your variant analysis or genotyping research
Profile Multiple Cytokines and Chemokines Simultaneously with Very High Sensi...QIAGEN
Learn how to profile multiple cytokines and chemokines simultaneously with very high sensitivity and specificity using the standard ELISA reader. Available in different formats to suit your research needs such as single-analyte, multi-analyte or custom mix-n-match format for human, mouse and rat.
This document discusses wet-lab considerations for Illumina sequencing data analysis. It describes the typical Illumina sequencing workflow including library preparation, cluster formation, sequencing, and data analysis. It provides details on DNA and RNA input requirements, library construction steps like fragmentation and adapter ligation, and quality control methods. The document also discusses newer sequencing technologies like Pacific Biosciences and Oxford Nanopore sequencing.
Precision medicine for oncology requires accurate and sensitive molecular characterization. However, sample degradation, polymerase errors, and sequencing errors reduce accuracy for sequencing genetic variants. By incorporating molecular tagged adapters in target enrichment, and using DNA probes that deliver extremely even and deep coverage, we are able to demonstrate a 300-fold reduction in false positives at or above 0.25% variant frequency. In this presentation, Dr Mirna Jarosz discusses these methods and how they can significantly reduce error rates in your sequencing data.
Single-cell microRNA expression profiling is a challenging workflow. From cell lysis, reverse transcription, preamplificatin to real-time PCR, every step involves technical pitfalls. Therefore it is critical to have a robust system that facilitates universal cDNA synthesis and universal amplification of all miRNAs in one workflow without introducing bias. Here we present a new poster – introducing a robust real-time PCR workflow and protocol for profiling miRNA expression from a single cell and how we analyze the single cells by using the free data analysis software.
This document discusses GeneRead DNAseq Targeted Exon Enrichment and the GeneRead Library Quantification System for next generation sequencing. It begins with an introduction and agenda, then discusses targeted enrichment including the workflow, principles, data analysis, pathway content, performance data, and an application example. It also discusses library quantification including the workflow and an application example. In summary, the document presents Qiagen's GeneRead DNAseq and Library Quant systems as targeted enrichment and library quantification solutions for next generation sequencing applications.
The document discusses GeneRead DNAseq Targeted Exon Enrichment and GeneRead Library Quantification System for Next Generation Sequencing. It provides an overview of the targeted enrichment workflow and principles, pathway-focused analysis tools, library quantification workflow, and performance data. The targeted enrichment panels allow users to focus sequencing on genes of interest, improve detection of low prevalence mutations from poor quality samples. The library quantification system uses qPCR to accurately quantify sequencing libraries and assess sample quality before NGS runs.
Analyzing Fusion Genes Using Next-Generation SequencingQIAGEN
Fusion genes are hybrid genes formed by the fusion of two separate genes. Translocation, interstitial deletion and chromosomal inversions are some of the genetic events that can lead to the formation of fusion genes. The occurrence of fusion genes and its implications in cancer have already been known, but the emergence of NGS technology – especially RNA sequencing – offers the potential to detect novel gene fusions. You can learn more about fusion genes and applying NGS to detect them at our upcoming webinar, presented by Raed Samara, Ph.D., QIAGEN’s Global Product Manager for NGS technologies.
In this webinar, Dr. Raed Samara will cover:
1. Fusion genes: what they are and a historical perspective
2. Fusion gene detection: the current status
3. RNA sequencing vs. digital RNA sequencing
4. How to detect and accurately quantify novel fusion genes in your sample
QIAseq Targeted DNA, RNA and Fusion Gene PanelsQIAGEN
Tumor heterogeneity has been known for a while but quantifying heterogeneity is still a challenge. NGS is the method of choice in the analysis of tumor heterogeneity, however, there are some inherent challenges associated with it. These include false positives, gaps in the gene due to overrepresentation and incomplete representation of low-frequency transcripts – all contributing to an inaccurate picture. Conventional library prep strategies for NGS are based on PCR, which introduces sequence-based bias and amplification noise, leading to these inaccuracies. In this webinar, we will cover
1. Principles of UMI and the new QIAseq product porfolio
2. How UMI along with SPE (single primer extension) allows for increased uniformity across difficult-to-sequence regions, removal of library construction bias, improved data analysis and sequencing optimization
3. How data generated from using UMI and SPE is directly comparable to analysis derived from whole transcriptome and exome sequencing
4. Application of UMI and SPE in the discovery of novel gene fusions and in the analysis of gene expression and genetic variation
Semi Automated Low-throughput Workflow for Microbial Analyses of Human StoolQIAGEN
The gut microbiota composition changes dramatically throughout aging and disease. A healthy gut microbiota is typically characterized by large bacterial taxonomic diversity and functional capacity, whereas frailty and aging are associated with loss of diversity and expansion of more pathogenic bacterial species. However, in order to accurately profile changes in microbial communities, the reproducible isolation of high-quality DNA is an important step. Automation enables reliable and reproducible isolation of DNA of superior quality, which can be used directly for downstream sequencing applications.
This webinar focuses on the development of a semi-automated workflow to profile the gut microbiota of young and old individuals and identify changes in bacterial composition and function that occur with age. This workflow will help to simplify and streamline the DNA extraction process for samples with high inhibitor content and subsequent microbial community analyses.
Achieve Complete Coverage of the SARS-CoV-2 GenomeCamille Cappello
Utilize multiple overlapping amplicons in a single tube, using a rapid, 2-hour workflow to prepare ready-to-sequence libraries. The PCR1+PCR2 workflow generates robust libraries even from low input quantities of DNA that may be subsequently quantified and normalized with conventional methods such as Qubit® or Agilent Bioanalyzer, or optionally using the included Swift Normalase reagents.
Provides coverage of >99% of the SARS-CoV-2 genome from limited viral titers
Application Note: A Simple One-Step Library Prep Method To Enable AmpliSeq Pa...QIAGEN
Targeted amplicon sequencing is a cost-effective, convenient and rapid method for variant detection. This application note outlines a straightforward workflow that uses the QIAseq 1-Step Amplicon Library kit to verify AmpliSeq targeted sequencing assays on the Illumina sequencing instruments. By combining end-repair and ligation, the QIAseq 1-Step Amplicon Library Kit offers a fast and efficient 30-minute procedure for the preparation of high-quality, artifact-free Illumina libraries from any PCR amplicons, including AmpliSeq Panels.
With technological breakthroughs in single cell isolation, whole genome amplification (WGA) and NGS library preparation, experiments using single cells are now possible. However, challenges still exist. In particular, methods for the unbiased and complete amplification of a single genome and for the efficient conversion of that amplified DNA into a sequencer-compatible library face several technical limitations including incomplete amplification, the introduction of PCR errors, GC-bias and locus or allelic drop-out. The presentation covers the impact of these factors and how one can mitigate it.
Advanced NGS Library Prep for Challenging SamplesQIAGEN
This document discusses advanced next-generation sequencing (NGS) library preparation methods for challenging samples. It introduces NGS applications using various sample types and sizes. Standard NGS library preparation kits have input requirements that cannot accommodate many sample types and quantities. New techniques optimized for sub-nanogram inputs can construct high-quality libraries from as little as 10 picograms of DNA. These methods show consistent conversion across a wide input range and enable applications like ancient DNA analysis and circulating tumor DNA detection from blood. The document focuses on cell-free DNA library preparation challenges and solutions like the QIAGEN cfDNA library kits.
The transcriptome of a cell is not fixed, but is dynamic, and reflects the function or type of the cell, the cell stage or the cell's response to intrinsic and extrinsic influences, such as signaling or stress factors. Only on a single cell level, can you eliminate the biological noise that is inherent to standard gene expression analysis – providing you the insights needed for a deeper understanding of transcription dynamics. In this presentation we delve into the different steps of RNA seq starting from a single cell.
Next-generation genomics: an integrative approachHong ChangBum
This document summarizes a presentation on next-generation genomics and integrative analysis. It discusses the types of genomic data available from techniques like genome sequencing, RNA sequencing, ChIP-seq, and epigenomics. It explains that integrative analysis can help annotate functional features, infer variant function, and understand gene regulation. Approaches to integration include data reduction, unsupervised clustering, and supervised Bayesian networks. Large-scale datasets can be accessed through browsers, add-ons, and standalone tools to generate novel hypotheses. Future work includes more integrated community resources with search capabilities.
1) The document discusses different whole genome amplification techniques for obtaining DNA from single cells, including PCR-based and PCR-free methods.
2) It provides comparisons of different whole genome amplification kits, finding that QIAGEN's REPLI-g Single Cell Kit has the highest genome coverage, lowest duplication rates, and best performance for detecting copy number variations and single nucleotide variations, making it optimal for single cell sequencing applications.
3) Case studies demonstrate that the REPLI-g Single Cell Kit provides more uniform coverage and significantly fewer sequencing errors compared to the MALBAC method.
Exploring new frontiers with next-generation sequencingQIAGEN
The document describes several next-generation sequencing products from QIAGEN, including the QIAseq Targeted RNA Panels, QIAseq Targeted RNAscan Panels, QIAseq Targeted DNA Panels, QIAseq 1-Step Amplicon Library Kit, QIAseq Ultralow Input Library Kit, and QIAseq cfDNA All-in-One Kit. These products are designed to simplify NGS workflows and provide high-quality libraries from low input samples in order to maximize insights from applications such as single-cell analysis, liquid biopsies, and metagenomics.
Alzheimer’s disease (AD) is a devastating neurodegenerative disease that is genetically complex. Although great progress has been made in identifying fully penetrant mutations in genes that cause early-onset AD, these still represent a very small percentage of AD cases. Large-scale, genome-wide association studies (GWAS) have identified at least 20 additional genetic risk loci for the more common form: late-onset AD. However, the identified SNPs are typically not the actual risk variants, but are in linkage disequilibrium with the presumed causative variants [1].
To help identify causative genetic variants, we have combined highly accurate, long-read sequencing with hybrid-capture technology. In this collaborative webinar*, we present this method and show how combining IDT xGen® Lockdown® Probes with PacBio SMRT® Sequencing allows targeting and sequencing of candidate genes from genomic DNA and corresponding transcripts from cDNA. Using a panel of target capture probes for 35 AD candidate genes, we demonstrate the power of this approach by looking at data for two individuals with AD. Some additional benefits of this method include the ability to leverage long reads, phase heterozygous variants, and link corresponding transcript isoforms to their respective alleles.
Reference: 1. Van Cauwenberghe C, Van Broeckhoven C, Sleegers K. (2016) The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet Med, 18(5):421–430.
* This presentation represents a collaboration between Pacific Biosciences and Integrated DNA Technologies. The individual opinions expressed may not reflect shared opinions of Pacific Biosciences and Integrated DNA Technologies.
The Importance of Quality Control Steps in ExperimentsQIAGEN
From starting material to final results, every analysis workflow is a journey to unlock the biological information within your sample without altering it, and high-quality results are only achieved from high-quality samples.
Within each step, lie challenges directly related to the sample type and analysis technologies, and at each step, there is potential for multiple things to go wrong, jeopardizing your experiments, results and reputation. Therefore, standardizing samples and performing relevant quality control after critical steps is of utmost importance to ensure the quality and reproducibility of results, as well as reliable interpretation.
In this webinar, we will introduce you to the main sample quality parameters and their respective impact on downstream applications, discuss how to monitor them and cover the advantages of automating quality control along complex workflows.
Targeted RNAseq for Gene Expression Using Unique Molecular Indexes (UMIs): In...QIAGEN
Traditional RNA sequencing (RNA-Seq) is a powerful tool for expression profiling, but is hindered by PCR amplification bias and inaccuracy at low expressing genes. QIAseq RNA is a flexible and precise tool developed for mitigating these complications, allowing digital gene expression analysis. This in-depth webinar will cover sample requirements, experimental design, NGS platform-specific challenges and workflow for gene enrichment, library prep and sequencing. The applications of QIASeq RNA Panels in cancer research, stem cell differentiation and elucidating the effects small molecules on signaling pathways will be highlighted.
IDT provides a range of solutions for targeted next generation sequencing. Labs processing hundreds to thousands of samples can create highly uniform, custom panels using xGen® Lockdown Probes. The new xGen Acute Myeloid Leukemia (AML) panel is a predesigned set of Lockdown Probes that captures 260 genes identified by whole genome and exome sequencing of 200 patient samples. The AML panel can be used as stand-alone or customized with additional probes to detect other targets of interest.
New Progress in Pyrosequencing for Automated Quantitative Analysis of Bi- or ...QIAGEN
Pyrosequencing is a highly flexible technology based on sequencing-by-synthesis for the rapid and quantitative analysis of any type of sequence variation. The real-time output delivers high-resolution sequence information, making pyrosequencing highly suitable for applications ranging from biallelic or multiallelic SNP analysis, DNA methylation quantification to complex mutation analysis of multiple sequence variations in a single run.
In this slideeck, we introduce the new PyroMark Q48 Autoprep system which enables fully automated template preparation integrated in the pyrosequencing workflow. In addition, a new Multiple Primer Dispensation (MPD) strategy is presented which allows fully automated dispensation of sequencing primer, offering a seamless workflow from samples to quantitative genotyping results.
This slidedeck focuses on the following topics
• Pyrosequencing technology and workflow in genotyping analysis
• Introduction into the new PyroMark Q48 Autoprep
• MPD strategy for a seamless automated pyrosequencing workflow
Join us and learn how you can apply the new pyrosequencing system and protocol to your variant analysis or genotyping research
Profile Multiple Cytokines and Chemokines Simultaneously with Very High Sensi...QIAGEN
Learn how to profile multiple cytokines and chemokines simultaneously with very high sensitivity and specificity using the standard ELISA reader. Available in different formats to suit your research needs such as single-analyte, multi-analyte or custom mix-n-match format for human, mouse and rat.
This document discusses wet-lab considerations for Illumina sequencing data analysis. It describes the typical Illumina sequencing workflow including library preparation, cluster formation, sequencing, and data analysis. It provides details on DNA and RNA input requirements, library construction steps like fragmentation and adapter ligation, and quality control methods. The document also discusses newer sequencing technologies like Pacific Biosciences and Oxford Nanopore sequencing.
Precision medicine for oncology requires accurate and sensitive molecular characterization. However, sample degradation, polymerase errors, and sequencing errors reduce accuracy for sequencing genetic variants. By incorporating molecular tagged adapters in target enrichment, and using DNA probes that deliver extremely even and deep coverage, we are able to demonstrate a 300-fold reduction in false positives at or above 0.25% variant frequency. In this presentation, Dr Mirna Jarosz discusses these methods and how they can significantly reduce error rates in your sequencing data.
Single-cell microRNA expression profiling is a challenging workflow. From cell lysis, reverse transcription, preamplificatin to real-time PCR, every step involves technical pitfalls. Therefore it is critical to have a robust system that facilitates universal cDNA synthesis and universal amplification of all miRNAs in one workflow without introducing bias. Here we present a new poster – introducing a robust real-time PCR workflow and protocol for profiling miRNA expression from a single cell and how we analyze the single cells by using the free data analysis software.
This document discusses GeneRead DNAseq Targeted Exon Enrichment and the GeneRead Library Quantification System for next generation sequencing. It begins with an introduction and agenda, then discusses targeted enrichment including the workflow, principles, data analysis, pathway content, performance data, and an application example. It also discusses library quantification including the workflow and an application example. In summary, the document presents Qiagen's GeneRead DNAseq and Library Quant systems as targeted enrichment and library quantification solutions for next generation sequencing applications.
The document discusses GeneRead DNAseq Targeted Exon Enrichment and GeneRead Library Quantification System for Next Generation Sequencing. It provides an overview of the targeted enrichment workflow and principles, pathway-focused analysis tools, library quantification workflow, and performance data. The targeted enrichment panels allow users to focus sequencing on genes of interest, improve detection of low prevalence mutations from poor quality samples. The library quantification system uses qPCR to accurately quantify sequencing libraries and assess sample quality before NGS runs.
Target enrichment enables researchers to focus their next generation sequencing (NGS) efforts on regions of interest, allowing them to obtain more sequencing data relevant to their study. In-solution target capture is a method of enrichment using oligonucleotide probes directed to specific regions within a genome. Target capture can be used to enrich multiple samples simultaneously, reducing the cost per sample, while using individually synthesized probes allows researchers to construct gene panels that can be optimized over time.
Overview of the commonly used sequencing platforms, bioinformatic search tool...OECD Environment
24 June 2019: This OECD seminar presented and discussed the potential use of genome sequence, bioinformatic tools and databases in a regulatory decision process for microbial pesticides.
VarSeq 2.6.0: Advancing Pharmacogenomics and Genomic AnalysisGolden Helix
In the rapidly evolving field of genomic analysis, staying current with the latest research, data sources, and test advancements is crucial. In this webinar, we review how VarSeq addresses the needs to stay on top of the latest with the release of VarSeq 2.6.0.
This release features an exome-optimized workflow for LOH and CNV calling as well as the introduction of VSPGx to produce pharmacogenomic reports for gene panels as well as exomes and genomes. With the recent release of gnomAD v4, we have had many requests for the integration of this large update to the most population frequency source. With VarSeq 2.6.0, the latest version of gnomAD has been integrated into VSClinical and the updated tracks spans beyond variants to cover CNVs and gene scores to update all your workflows to the latest data.
In this webcast, we will cover.
Improved VS-CNV performance and updated exome analysis workflows.
Pharmacogenomics in action: Utilizing VSPGx for exome and genome assessments.
gnomAD v4 in practice: Updated automated and manual variant interpretation workflows.
Join us for an insightful session on the latest VarSeq 2.6.0 features, bringing you the most up-to-date data and workflows for your genomic analysis.
The document describes QIAGEN's GeneRead DNAseq Targeted Exon Enrichment and GeneRead Library Quantification System for next generation sequencing. It discusses targeted enrichment workflow and principles, data analysis, pathway content of panels, performance data and application examples. It also covers the library quantification workflow, using qPCR to quantify sequencing libraries, and a DNAseq library quantification array to assess sample quality. The document is aimed at promoting these NGS sample preparation and analysis solutions to potential customers.
Course: Bioinformatics for Biomedical Research (2014).
Session: 2.1.2- Next Generation Sequencing. Technologies and Applications. Part II: NGS Applications I.
Statistics and Bioinformatisc Unit (UEB) & High Technology Unit (UAT) from Vall d'Hebron Research Institute (www.vhir.org), Barcelona.
Genome in a Bottle - Towards new benchmarks for the “dark matter” of the huma...GenomeInABottle
The document discusses Genome in a Bottle (GIAB) and its efforts to characterize human genomes and provide reference materials and benchmarks to evaluate genome sequencing and variant calling. Specifically, it summarizes how GIAB has characterized 7 human genomes, provides extensive public sequencing data for benchmarking, and is now using linked and long reads to expand the small variant benchmark set, develop a structural variant benchmark, and perform diploid assembly of difficult regions. It also shows how new benchmarks that include more difficult regions have revealed errors in previous benchmarks and reduced performance metrics for variant calling tools.
Step by Step, from Liquid Biopsy to a Genomic Biomarker: Liquid Biopsy Series...QIAGEN
Liquid biopsies enable us to monitor the evolution of genetic aberrations in primary tumors as they shed the tumor cells into the circulation. The limitation is the ability to detect these low frequency genetic aberrations in a consistent manner to understand short- and long-term implications and how this information will be used in the clinic. This slidedeck will cover the challenges and solutions associated with multiple steps as one starts with liquid biopsy and move towards finding a new biomarker.
The document discusses different strategies for next generation sequencing in clinical practice, including PCR-based and hybridization-based capture methods. It compares methods such as Raindance, Fluidigm, and Agilent SureSelect custom capture on various disease panels. It finds that hybridization-based capture provides more even coverage and reliable allele ratios than PCR-based methods. It recommends Illumina's TruSeq Custom Amplicon sequencing for high-throughput clinical tests due to reduced sample preparation time and cost.
March 21, 2017 - Biogazelle’s CSO prof Jo Vandesompele presented Biogazelle’s strategy and expertise to deploy RNA in liquid biopsies to further diagnostic applications and drug development at “Revolutionizing next-generation sequencing” (Antwerp, Belgium).
In contrast to general belief, a substantial part of the human protein coding transcriptome is abundantly present in the blood as extracellular mRNA, ready to exploited. Here, Jo presents probe based mRNA capture as a sensitive RNA sequencing workflow to study thousands of mRNA genes in cell-free RNA from cancer patients’ plasma. Apart from RNA abundance profiling, this type of data can also be use to detect structural RNA variants, such as somatic mutations, and RNA editing events, all known to play an important role in cancer. RNA capture sequencing enables liquid biopsy guided precision oncology, such as therapy stratification, treatment response monitoring and early detection of relapse.
The document discusses Cignal Lenti Reporter Assays for analyzing signaling pathways in mammalian cells. It describes:
1) The challenges of traditional cell-based signaling assays such as poor reproducibility, low sensitivity, and inability to study non-transfectable cell types.
2) How the Cignal Lenti Reporters address these challenges by using optimized transcriptional response elements and reporter genes engineered for high performance, and lentiviral delivery which allows transduction of any cell type.
3) The product breadth including over 45 pathways covered, dual reporter formats of luciferase and GFP, and array formats for studying multiple pathways simultaneously.
This document discusses oncogenomics and cancer genomics technologies. It provides an overview of oncogenomics, the types of DNA biomarkers studied including mutations, and experimental strategies used for cancer genomics research. Key techniques discussed are next-generation sequencing, quantitative PCR (qPCR), and mass spectrometry. The document compares different technologies for mutation detection and profiling and their sensitivities. It also outlines the specifications and pipeline for developing a qPCR-based somatic mutation assay.
A targeted subgenomic approach for phylogenomics based on microfluidic pcr an...SimonUribeConvers
We describe a new method for generating large amounts of genomic data using microfluidic PCR and high-throughput sequencing. We also have a new way to process the raw information and are able to recover not only 50,000 base pairs for ~500 samples but also the alleles for each individual sample.
This is a presentation that I gave at the conference Botany2014 in Boise, Idaho, USA.
This document summarizes the Genome in a Bottle (GIAB) Consortium's efforts to characterize structural variants in human genomes to serve as benchmarks. The GIAB Consortium has generated structural variant calls for 7 human genomes using diverse data types and analysis methods. The document describes the GIAB Consortium's process for integrating these data to identify high-confidence structural variant calls to include in version 0.6 of the structural variant benchmark set. It provides examples of different types of structural variants characterized and evaluates the trustworthiness of the benchmark calls based on independent validation. The document also discusses ongoing efforts to further improve structural variant characterization using emerging long-read technologies.
Next Generation Diagnostics: Potential Clinical Applications of Illumina’sTec...Ilya Klabukov
Illumina's technology has potential clinical applications in molecular diagnostics. Their sequencing platforms like MiSeq and analysis software like KaryoStudioDx can enable molecular cytogenetic testing and targeted gene panels. MiSeq allows scalable amplicon sequencing from hundreds to thousands of targets in 1-2 days at lower costs than Sanger sequencing. Illumina aims to submit their iScan platform and arrays for FDA approval for post-natal cytogenetic testing. Their SNP microarrays can detect more types of chromosomal abnormalities than microarrays and help characterize regions associated with disease.
One-Stop Antibody Drug Discovery Services from GenScript ProBioGenScript ProBio
GenScript ProBio is the biopharmaceutical division of GenScript, a leading biotech company. GenScript ProBio provides end-to-end services from drug discovery to commercialization, including antibody discovery and development, cell line development, process development, and clinical manufacturing. Key services include antibody humanization, developability assessment, and affinity maturation to improve antibody candidates for preclinical and clinical development.
The document describes Cignal Reporter Assays from SABiosciences that enable simple and robust analysis of signal transduction pathways. The assays utilize dual-luciferase reporters containing optimized transcriptional regulatory elements and luciferase variants to provide high sensitivity and low variability. The assays allow monitoring of 29 pathways and are available in different formats for various cell types and applications like RNAi and small molecule screening.
- Video recording of this lecture in English language: https://youtu.be/Pt1nA32sdHQ
- Video recording of this lecture in Arabic language: https://youtu.be/uFdc9F0rlP0
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
The skin is the largest organ and its health plays a vital role among the other sense organs. The skin concerns like acne breakout, psoriasis, or anything similar along the lines, finding a qualified and experienced dermatologist becomes paramount.
Travel vaccination in Manchester offers comprehensive immunization services for individuals planning international trips. Expert healthcare providers administer vaccines tailored to your destination, ensuring you stay protected against various diseases. Conveniently located clinics and flexible appointment options make it easy to get the necessary shots before your journey. Stay healthy and travel with confidence by getting vaccinated in Manchester. Visit us: www.nxhealthcare.co.uk
These lecture slides, by Dr Sidra Arshad, offer a simplified look into the mechanisms involved in the regulation of respiration:
Learning objectives:
1. Describe the organisation of respiratory center
2. Describe the nervous control of inspiration and respiratory rhythm
3. Describe the functions of the dorsal and respiratory groups of neurons
4. Describe the influences of the Pneumotaxic and Apneustic centers
5. Explain the role of Hering-Breur inflation reflex in regulation of inspiration
6. Explain the role of central chemoreceptors in regulation of respiration
7. Explain the role of peripheral chemoreceptors in regulation of respiration
8. Explain the regulation of respiration during exercise
9. Integrate the respiratory regulatory mechanisms
10. Describe the Cheyne-Stokes breathing
Study Resources:
1. Chapter 42, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 36, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 13, Human Physiology by Lauralee Sherwood, 9th edition
10 Benefits an EPCR Software should Bring to EMS Organizations Traumasoft LLC
The benefits of an ePCR solution should extend to the whole EMS organization, not just certain groups of people or certain departments. It should provide more than just a form for entering and a database for storing information. It should also include a workflow of how information is communicated, used and stored across the entire organization.
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central19various
Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central Clinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa CentralClinic ^%[+27633867063*Abortion Pills For Sale In Tembisa Central
Promoting Wellbeing - Applied Social Psychology - Psychology SuperNotesPsychoTech Services
A proprietary approach developed by bringing together the best of learning theories from Psychology, design principles from the world of visualization, and pedagogical methods from over a decade of training experience, that enables you to: Learn better, faster!
8 Surprising Reasons To Meditate 40 Minutes A Day That Can Change Your Life.pptxHolistified Wellness
We’re talking about Vedic Meditation, a form of meditation that has been around for at least 5,000 years. Back then, the people who lived in the Indus Valley, now known as India and Pakistan, practised meditation as a fundamental part of daily life. This knowledge that has given us yoga and Ayurveda, was known as Veda, hence the name Vedic. And though there are some written records, the practice has been passed down verbally from generation to generation.
2. swiftbiosci.com
Swift Library Prep Overview: IP families
Adaptase
2S/Amplicon
Normalase
Accel-NGS Methyl-Seq
For quant-free
library pooling
Accel-Amplicon or
SNAP Amplicon
(Single-tube multiplex PCR)
Swift 2S Turbo
Accel-NGS 2S
(PCR-free, Plus, Hyb)
Accel-NGS 1S
Accel-NGS
For Ion Torrent
Adaptase Module
(single cell methyl)
Accel-NGS XL
for PacBio
Swift RNA
Swift Rapid RNA
Done:
7th Dec Swift Product for Metagenomics Study
21st Dec Swift Product for Virus Study
More Distributor Training:
Feb 2021 Swift Product for Very Specific Application
Not covered product
Swift 2S Sonic
3. swiftbiosci.com
Today’s Topic
Cancer Study
Genomic
Sequencing
RNA
Sequencing
Swift RNA library kit
Swift Rapid RNA library kit
After this training session:
• Able to know benefit of choosing each Swift DNA/ RNA library prep kit for cancer study
• Able to know why choose amplicon workflow and why Swift amplicon product
Amplicon
Panel
Hyb Capture
Swift DNA library prep kit+
Swift hyb capture panel / 3rd party panel
• Accel-NGS 2S kit
• Accel-NGS 1S kit
• 2S Turbo
• 2S Sonic
DNA
Methylation
WGS
Swift gene/cancer-
based panel
Somatic/germline
mutation detection
Fusion gene
Alternative splicing
RNA expression
Rare & novel transcripts
Disease-associate SNV
…
Hyb Capture WGBS
Swift Methyl-seq Kit+
Arbor Bio myBaits MethylCap
Swift Methyl-seq Kit
Hyb Capture RNA-seq
Swift RNA library kit or
Swift Rapid RNA library kit
+
Swift hyb capture panel / 3rd
party panel
4. swiftbiosci.com
Type of Mutation in Cancer
(1) Inherited (blood spot, whole blood, buccal swab, agricultural)
An inherited gene mutation is present in the egg or sperm that formed the
child.
Germline mutation (because the cells that develop into eggs and sperm
are called germ cells) or hereditary.
Inherited mutations are thought to be a direct cause of only a small fraction
of cancers.
Germline calling where VAF = 50% or 100%
(2) Acquired (Fresh frozen tissue, FFPE, cfDNA/ctDNA)
An acquired mutation is not present in the zygote, but is acquired some
time later in life. Somatic mutation
Type:
- Substitutions of one base by another
- Insertions or deletions of small or large segment of DNA
- Rearrangement (DNA has been broken and then rejoined to a DNA segment
from elsewhere in the genome)
- Copy number increase (increases from the two copies present in the normal
diploid genome, also know as gene amplification)
- Copy number reductions
https://www.cancer.org/cancer/cancer-causes/genetics/genes-and-cancer/gene-changes.html
Landscape of somatic mutations present in a single
cancer genome
Nature. 2009 April 9; 458(7239)
8. swiftbiosci.com
2S Turbo 2S Sonic
Differentiators: Enzymatic fragmentation, fast and easy prep,
competitive price point, flexible adapter options
Key Applications: WGS (complex and/or small genomes), Targeted
(exome, panels), Genotyping by NGS, CNVs, Metagenomics
Target Customer: Production scale laboratories, such as: large PI,
core lab and service providers
Sample Types: gDNA, high quality FFPE, RNA (1st strand cDNA)
Input Range: 1-250 human or microbial (3rd party adapters),
50-250ng human or 1-250ng microbial (Swift adapter)
Differentiators: Mechanical Shearing, fast and easy prep, competitive
price point, flexible adapter options
Key Applications: WGS (complex and/or small genomes), Targeted
(exome, panels), Genotyping by NGS, CNVs, Metagenomics
Target Customer: Production scale laboratories, such as: large PI, core
lab and service providers
Sample Types: gDNA, high quality FFPE, cfDNA
Input Range: 1ng-1ug human or microbial
1S Plus Adaptase 2S (Plus, Hyb, PCR-Free)
Differentiators: ssDNA or ss/dsDNA mix, nicked DNA, RNA (1st
strand cDNA), viral genome, highly degraded/ancient DNA, short
fragments >40 bp…WHEN 2S FALLS SHORT!
Key Applications: WGS/ Hyb, ChIP-Seq, Metagenomics
Target Segment: Infectious Disease, Agriculture,
Archeology/Museum, Forensics, Biotechnology, Biopharma, Academic
and Government Labs
Sample Types: highly degraded FFPE, Ancient DNA, degraded
cfDNA, Very Low Input ChIP samples
Input Range: >10pg
Differentiators: Mechanical Shearing, degraded or dilute
samples such as FFPE and cfDNA
Key Applications: WGS (complex and/or small genomes), Targeted
(exome, panels), ChIP-Seq, low frequency variant detection, CNV
Target Customer:
Sample Types: gDNA, FFPE, cfDNA, RNA (1st strand cDNA) amplicons
Input Range: >10 pg (w/ PCR)
10 ng (cfDNA PCR-Free)
100 ng (gDNA PCR-Free)
Swift Product Selection and Positioning Guide
9. swiftbiosci.com
Turbo Turbo
New!! Swift 2S Turbo DNA Library Kits
for Illumina® platforms
With Enzymatic Shearing
Tissue or Blood Sample Type for Cancer Study
10. swiftbiosci.com
Custom adapter guide(IDT): https://sfvideo.blob.core.windows.net/sitefinity/docs/default-source/supplementary-product-info/idt-custom-ngs-adapters-product-sheet.pdf?sfvrsn=45d71f07_6
Minimal enzymatic incubation
&
purification steps
Indexing PCR
Time varies
Optional PCR
Terminal primers (included)
to increase library yield
Time varies
Ligation
3’ and 5’ ligation of P7 and p5
full-length adapters(Your choice of adapter)
truncated adapters
Flexible
✔️1-250 human
or microbial
✔️ PCR-free
Flexible
New! Swift 2S Turbo V2 DNA Library Kits will
launch soon
Choice of Kits: Standard & flexible
Standard
✔️50-250 human
or 1-250ng microbial
✘ PCR-free
12. swiftbiosci.com
Swift 2S Turbo Library Kit was
evaluated for enrichment using Swift
Exome and Pan-Cancer Hyb Panels.
Comprehensive target coverage and
high complexity was observed with
multiple sample types, input
quantities, and platforms. Coverage
uniformity and complexity was higher
with low input Turbo libraries
compared to competitors (see
highlighted region of table).
Turbo’s efficient library provide
more data at low input !
*FFPE and HD200 sample integrity quantified by qPCR using the Swift ALU repeat assay provide with the Swift library prep kits, 0.34 ratio obtained for both samples.
Benchmarking: Hyb Capture Better Coverage
Uniformity with low input
13. swiftbiosci.com
*FFPE and HD200 sample inputs quantified via qPCR of smaller ALU 115 repeat.
+Based on 247/115 ALU repeat fragment ratios
Sample
Integrity+
Input
(ng)*
%Duplicates
Mean Bait
Coverage
%Covered
≥ 20X
%Covered
≥ 50X
%Covered
≥ 100X
% Bases On-Target
0.24 25 6 176X 99.5 98.3 90.7 73.8
0.26 25 8 173X 99.6 98.5 94.6 74.9
0.34 24 4 163X 99.1 98.1 89.7 70.3
0.34 79 6 151X 99.4 98.5 90.2 69.6
Uniform Coverage for Somatic Mutation Detection
Targeted Sequencing of FFPE using Swift Exome Panel (MiSeq Run)
Sequencing metrics of FFPE samples match control samples
(e.g. NA12878 % bases on target = 68-75%).
14. swiftbiosci.com
Swift Deceleration Module to control fragmentation
reaction time for automation
15 uL
10 uL
3 uL
1.5 uL
5 uL
Reagent DE
into frag
reaction
Fragment
Mode (bp)
1.5 uL 382
3 uL 434
5 uL 467
10 uL 600
15 uL 750
Automation Request
• Slow fragmentation to 15 min for 350-400bp
• Prepare reaction at room temp
• Sample placed on cycler 10 min after adding fragmentation mix
Actions
• Tested various volumes of Reagent DE in fragmentation reaction
• Ensured reproducible fragmentation, and no influence in Exome Capture
Will be added to Turbo protocol
☺︎ large insert size (>350bp) (ie, metagenomics)
☺︎ Automation
☺︎ SOP
☺︎ Similar fragment time for various condition of degraded
samples
16. swiftbiosci.com
Swift 2S: Superior Data Quality
High adapter ligation efficiency
Unique 3’ end repair that efficiently converts all 3’-P into 3’-OH and at
the same time prevents chimera formation
Unique 5’ end repair that replaces bases damaged by physical
shearing
No A-tailing
No adapter titration for low inputs maintains high ligation efficiency
Very low adapter dimers
Introduces Molecular ID tags (MIDs)
Best Data Quality
WGS and exome sequencing
Metagenomic sequencing (ultra-low inputs <1ng down to 10 pg)
ChIP-Seq (including ultra-low inputs down to 10 pg)
FFPE and cfDNA/ctDNA (>10 ng PCR-Free)
HiC-Seq (as low as 5000 cells)
18. swiftbiosci.com
2S Hyb Performance with Fixed Samples
of Various Fixation Times and Input Levels
Fixation Time Course with the Pan-Cancer Panel
Accel-NGS® 2S Hyb libraries were constructed with 100, 10, and 1 ng of DNA. DNA extracted from the same
normal kidney sample which had either been fresh-frozen or fixed for 6, 24, or 48 hours before being paraffin-
embedded. Amplified libraries were enriched with the IDT xGen® Pan-Cancer Panel. The xGen Pan-Cancer Panel is
0.9Mb and all samples were normalized to 0.6Mb reads.
INPUT
QUANTITY
SAMPLE
TYPE
%
ALIGNED
%
DUPLICATION
MEAN BAIT
COVERAGE
% COVERED
> 1X
% COVERED
> 20X
% BASES ON
TARGET
100 ng
Frozen 96 1 42X 99 91 80
6 Hr. Fix 96 1 43X 99 93 81
24 Hr. Fix 97 1 44X 99 93 82
48 Hr. Fix 97 1 45X 99 88 82
10 ng
Frozen 96 3 42X 99 90 80
6 Hr. Fix 96 5 41X 99 92 80
24 Hr. Fix 97 4 42X 99 93 81
48 Hr. Fix 97 8 42X 99 86 81
1 ng
Frozen 95 18 33X 99 85 77
6 Hr. Fix 94 32 26X 99 77 74
24 Hr. Fix 95 31 27X 100 79 76
48 Hr. Fix 95 44 22X 99 53 73
19. swiftbiosci.com
Choice of Index- MID
Enable accurate de-duplication from single read sequencing,
and distinguishing PCR duplicates from fragmentation and
strand duplicates.
Posters
9 base
N sequence
6 or 8 base
20. swiftbiosci.com
Choice of Index- MID
Only 1x coverage
was retained post-
deduplication
increase in data
retention up to 6x
coverage post
deduplication.
21. swiftbiosci.com
MID Enable Ultra-Low Frequency Variant
Detection
cfDNA was extracted from blood of four individuals
with unique genetic background and Coriell gDNA
samples from different genetic backgrounds were
obtained. To determine the effect of MIDs on low
frequency variant calling, sample spike-ins were
performed at 1% or 0.5% frequency into 10 ng
cfDNA or 100 ng gDNA. Libraries were prepared
with the Swift 2S Hyb kit with MIDs, enriched with
the Swift Pan-Cancer Hyb Panel , and sequenced
on an Illumina HiSeq ® to a minimum of 8000x
coverage. A consensus sequence was generated
for each MID family (BMFtools) and data were
analyzed for homozygous SNPs present in the
spike-in sample only. 6/6 known variants were
present in all three 1% cfDNA samples and 27/27
known variants were present in both 1% and 0.5%
gDNA samples depicting the power of MIDs for low
frequency variant calling.
22. swiftbiosci.com
Patient- derived xenografts (PDX)
CTC-derived xenografts (CDX)
Cancer Discov; 6(3); 286–99.
Cancer Research UK Manchester Institute
WES + multiplex PCR panel, long term monitoring
response of sequential targeted, immuno- and
chemotherapy of one melanoma patient.
10-25 ng cfDNA WES) swift 2S
Cancer Research UK Manchester Institute
• 214 patients (364 samples) with stage II, III, IV
melanoma
• 13ng cfDNA (WES on Miseq) swift 2S )
• Application:
Facilitate individualized treatment decisions for
patients with advanced melanoma
Publication for Clinical-based
23. swiftbiosci.com
Part A (100 patients,22 tumor type) Part B (450
patients)
Workflow establishment & test its feasibility
Workflow for ctDNA test:
4x 10mL Streck
↓
Manual purification: QIAmp Circulating Nucleic Acid Kit (Qiagen)
Automation purification: :QIAsymphony (Qiagen)
↓
0.5 to 25 ng ctDNA for Accel-NGS 2S DNA Library Kits
↓
SureSelectXT Reagent Kits (Agilent) 641-gene panel, 2.1Mb
↓
Illumina NextSeq 500, 2 × 150 bp
TARGET
(Tumor chARacterisation to Guide Experiment Target therapy)
Aim:
Use ctDNA to identify clinically actionable mutations in early
phase clinical trail patients with a range of advanced-stage
cancers.
Publication for Clinical-based
24. swiftbiosci.com
Accel 2S Plus – Best Coverage and Superior Variant Detection in ccfDNA
• Prostate cancer plasma sample
• Prepared 10ng ccfDNA with Accel 2S Plus,
along with 3 other library prep kits.
• Sequenced on Illumina HiSeqX
(2 x 150bp PE)
• Analyzed CNV, SNV and Indels
• Accel 2S Plus kit detected more variants
and specific SNVs, INDELs and CNVs.
• Accel 2S Plus provided the best coverage
Mauger, F., et al. Comparison of commercially available whole-genome sequencing kits for variant detection..., Sci Rep 10, 6190 (2020)
Publication for Methodology Comparison
26. swiftbiosci.com
Accel-NGS® 1S Plus Specifications
• Broad input range from 10 pg to 250 ng
• Adapt strands of DNA ≥ 40 bp long
• Simple, 2-hour protocol
• Offered for Ion Torrent™ and Illumina
®
• No end polishing step
Features
• Capture previously unattainable sequences
• Process more samples per day
• Use platform of choice
• Preserve input fragmentation patterns for
precise mapping of DNA insert ends
Benefits
Ion Torrent is a trademark of Thermo Fisher Scientific. Illumina is a registered trademark of Illumina, Inc.
Adaptase tail
Truncated P7 adapter
ssDNA
27. swiftbiosci.com
Cancer Research UK Cambridge Institute
200 patients (18 different cancer types)
65 plasma samples
90–150 bp
180–220 bp
250–320 bp
High ctDNA: breast, ovarian, lung, melanoma, colorectal, and cholangiocarcinoma
Low ctDNA: glioma, renal, pancreatic, and bladder cancers.
Mutant ctDNA is generally more fragmented than non-
mutant cfDNA (19 cancer patients)
Mutant DNA in plasma of patients with advanced cancer is consistently
shorter than predicted mono-, and di-nucleosomal DNA fragment lengths
28. swiftbiosci.com
6.4倍富集
4倍富集
Longitudinal plasma samples of a colorectal cancer patient
Detect tumor progression 60 and 87 days before by
imaging or unselected t-MAD analysis.
Improve the detection of response or disease progression
60 days
87 days
29. swiftbiosci.com
AUC = 0.97
(sens: 90% & spec:98%)
AUC = 0.64
4.19X
SNVs
Conclusion:Size selection of shorter plasma DNA fragments enriches ctDNA and assists in the identification of a
greater number of genomic alterations with both targeted and untargeted sequencing at minimal additional cost.
Increased number of mutations detected in plasma
(samples from 6 patients with HGSOC)
32. swiftbiosci.com
Feature Specification Benefit
Input Quantity
10 ng – 1 g total RNA
100 pg – 100 ng mRNA
Supports a Wide Range
Consistent Library Output
RNA Types
Supported
Poly(A)-enriched mRNA
Ribodepleted RNA
Total RNA
Supports Most RNA
Applications
Technology
Adaptase® tailing and ligation
of 1st strand cDNA
No 2nd Strand cDNA
No Adapter Titration
Lowest Dimers & Duplicates
Maintains Strandedness,
High Mapping & Detection
Time 4.5 hours
Save 1 hour vs. NEBNext®
Half the time of TruSeq®
Kit Reaction
Sizes
24 • 96 Evaluation and Adoption
Indexing
Options
Single • Combinatorial Dual
Unique Dual • Normalase
Flexible to Sequencers,
Workflows and Applications
Multiplexing
Capability
Up to 768 libraries Save Sequencing Costs
Automation
Compatible with Liquid
Handlers
Custom Packaging Available
Adopt at Scale
Fast
Lowest Inputs
Low Cost
Feature Specification Benefit
Input Quantity
100 ng – 1 g total RNA
5 ng – 100 ng mRNA
Supports a Wide Range
RNA Types
Supported
Poly(A)-enriched mRNA
Ribodepleted RNA
Total RNA
Supports Most RNA
Applications
Technology
Adaptase® tailing and ligation
of 1st strand cDNA
High Strandedness
No 2nd Strand cDNA
No Adapter Titration
Time 3.5 hours Fastest on Market
Kit Reaction
Sizes
24 • 96 Evaluation and Adoption
Indexing
Options
Single • Combinatorial Dual
Unique Dual • Normalase
Flexible to Sequencers,
Workflows and Applications
Multiplexing
Capability
Up to 768 libraries Save Sequencing Costs
Automation
Compatible with Liquid
Handlers
Custom Packaging Available
Adopt at Scale
Fastest
Lowest Cost
Swift Rapid RNA Library Kit
Accelerate Your RNA-Seq Discovery
Swift RNA Library Kit
Deepen Your RNA-Seq Discovery
33. swiftbiosci.com
Why not Poly(A)?
10ng RNA for Swift RNA Library Kit
100ng RNA for Swift Rapid RNA Library Kit
100pg RNA for Swift RNA Library Kit
5ng RNA for Swift Rapid RNA Library Kit
35. swiftbiosci.com
Capture Workflow for Lower Inputs
Swift RNA on FFPE samples
100 pg total RNA
20 PCR cycles
Yields > 20 nM
1:10 dilution loaded on Bioanalyzer HS DNA chip
10 ng total RNA
16 PCR cycles
Yields > 100 nM
HER2- Sample 1
DV200 = 54
HER2+ Sample 4
DV200 = 61
HER2- Sample 3
DV200 = 54
Confidential
HER2- Sample 1
DV200 = 54
HER2+ Sample 4
DV200 = 61 HER2- Sample 3
DV200 = 54
36. swiftbiosci.com
HER2-
Sample 4
DV200 = 73
327 bp
93 ng/uL
HER2+
Sample 6
DV200 = 48
296 bp
73 ng/uL
100 ng FFPE RNA input directly into Swift library prep kits
1:10 dilution loaded on Bioanalyzer HS DNA chip
Library details:
• 100 ng total RNA
• 2 min @ 94 C adjusted
fragmentation time
• Relaxed 1.8X SPRIs
throughout
• 12 PCR cycles
HER2-
Sample 4
DV200 = 73
318 bp
58 ng/uL
HER2+
Sample 6
DV200 = 48
282 bp
66 ng/uL
Capture Workflow for Both Swift Kits
Swift RNA& Rapid RNA Library Kits on FFPE RNA (pre-hyb)
Swift RNA Swift Rapid RNA
37. swiftbiosci.com
Today’s Topic
Cancer Study
Genomic
Sequencing
RNA
Sequencing
Swift RNA library kit
Swift Rapid RNA library kit
After this training session:
• Able to know benefit of choosing each Swift DNA/ RNA library prep kit for cancer study
• Able to know why choose amplicon workflow and why Swift amplicon product
Amplicon
Panel
Hyb Capture
Swift DNA library prep kit+
Swift hyb capture panel / 3rd party panel
• Accel-NGS 2S kit
• Accel-NGS 1S kit
• 2S Turbo
• 2S Sonic
DNA
Methylation
WGS
Swift gene/cancer-
based panel
Somatic/germline
mutation detection
Fusion gene
Alternative splicing
RNA expression
Rare & novel transcripts
Disease-associate SNV
…
Hyb Capture WGBS
Swift Methyl-seq Kit+
Arbor Bio myBaits MethylCap
Swift Methyl-seq Kit
Hyb Capture RNA-seq
Swift RNA library kit or
Swift Rapid RNA library kit
+
Swift hyb capture panel / 3rd
party panel
39. swiftbiosci.com
Adaptase-based (1S, Methyl, Module, RNA)
U U U
U U U
U U U
Powered by Swift’s Adaptase®
Technology
•Single-stranded tailing and ligation
•Template-independent reaction
•>90% efficiency
•US Patent 9,896,709
•Underlying technology of Swift Methyl-Seq and
Single Cell Methyl (Adaptase Module) and 1S
Plus Library Kit
Benefits to Methyl-seq
• >40bp retention
• Lower input requirement
• Able to use ss&dsDNA as library prep template
41. swiftbiosci.com
4841 participants
CCGA Study
PATHFINDER
Study
STRIVE Study SUMMIT Study
Current Status Follow-up (>5 year) Enroll Follow-up (5 year) Enrolling
Actual/Expected
Enrollment
15254 participants 6,200 participants
99481 participants
(women)
50,000 participants
Sample Type Blood and tumor tissue A single blood draw Blood Blood
Time Perspective/
Purpose
Prospective Screening Prospective Prospective
Actual Study Start
Date
August 2016 December 2019 February 2017 April 2019
Estimated
Completion
March 2024 June 2021 May 2025 August 2030
https://grail.com/clinical-studies/
On-going Clinical Trials
42. swiftbiosci.com
https://doi.org/10.1016/j.annonc.2020.02.011
4841 participants
Annals of Oncology
>50 Cancer type
Adrenal (cortical carcinoma and neuroendocrine),
ampulla of Vater, anus, appendix, bone, brain and spinal
cord, breast, cervical lymph nodes and unknown primary
tumors of the head and neck, cervix uteri, colon and
rectum, corpus uteri…
STRIVE study
Training set + 1587
Validation + 615
6689 total
WGBS vs. WGS vs. target sequencing
Population-level screening
43. swiftbiosci.com
Step 5
Targeted Enrichment
Sequenced fragments are
associated back to regions
of interest
Step 6
Median depth: 113 million
median unique on-target depth: 139X
150bp PE sequencing, NovaSeq
Step 1
CCGA :8 tubes of 10mL whole blood
STRIVE: 4 tubes of 10mL whole blood
(Streck)
Centrifuge:<5days,median <2 days
Step 4
Swift Methyl-seq kit for
library preparation
WGBS; 30X depth
(n=3,508)
Twist panel (17.2Mb)
1,116,720 CpG
(~10 regions)
7.5Mb hypomethylated sites
7.4Mb hypermethylated sites
2.3Mb target both
Step 3
Bisulfite conversion:
EZ-96 DNA Methylation Kit (Zymo)
≥0.99 conversation rate
Step 2
10mL plasma, 75ng cfDNA
Manual: QIAamp Circulating Nucleic Acid kit
Automation: MagMax kit (ThermoFisher)
44. Enroll population: progressing advanced cancers(2011-
2016)
Sample collection: 1-4mLplasma (ETDA tube
Purification: QIAamp Circulating Nucleic Acid kit (4.5-30ng,
avg 21.1ng)
BS: EZ DNA Methylation-Lightning Kit (Zymo Research)
Library Prep: Accel-NGS Methyl- Seq DNA Library Kit
(Swift Biosciences)
Hyb Capture: llumina TruSight Rapid Capture Kit
Sequencing: Illumina HiSeq 2500 (2x100 cycle)
~10,000x mean target coverage
Targeted Methylation Sequencing of Plasma Cell-free DNA for
Cancer Detection and Classification
MD Anderson Cancer Center, Phase I Clinical Trials
9223 CpG sites, 32 cancer
type
( hypermethylated in tumors )
Liu. L, F.Janku, et. Al, 2018. Annals of Oncology
37 samples from late phase of CRC
Cutoff 7.52
Sens: 94.4%
Spe: 100%
Performance Evaluation
Publication for Clinical-based
45. (A) Patients on therapy had lower
methylation rates
(B) Patients with lower methylation rates
(blue) had longer survival rates
(C) Patients with lower methylation rates
had longer time to treatment failure
(D) Positive correlation between
methylation score and best RECIS
(response) score
Liu. L, F.Janku, et. Al, 2018. Annals of Oncology
68 patients off therapy (83.8% sens)
14 patients on therapy (50% sens)
OS
Off-therapy
TTF
55 patients
10.4 months
4.4 months
1.6 months
2.8 months
Clinical validation(78 patients with advanced colorectal
cancer, non-small-cell lung cancer (NSCLC), breast cancer or
melanoma
Targeted Methylation Sequencing of Plasma Cell-free DNA for Cancer
Detection and Classification
MD Anderson Cancer Center, Phase I Clinical Trials
Publication for Clinical-based
46. swiftbiosci.com
Publication for Research-based
A large integrated study of WGS, WGBS and whole-transcriptome, first study to look at comprehensive methylation
landscape in metastatic prostate cancer.
Observed that 22% of tumors exhibited a novel epigenomic subtype associated with hypermethylation and somatic mutations
in these four driver genes: TET2, DNMT3B, and BRAF.
47. swiftbiosci.com
Publication for Research-based
Wu et al., 2020, The Journal of Clinical Investigation
Characterize the plasma methylome in mCRPC and identify
prostate cancer–specific methylation signatures.
University College London Cancer Institute
48. swiftbiosci.com
Publication for Methodology Development
Uses the methylation profiles of adjacent CpG sites on an individual read to
accurately identify the tumor cfDNA fraction in plasma.
CancerDetector-generated tumor burden percentages correlated well with
tumor size (0.87) and can thus be used to monitor disease progression and
treatment.
This publication describes CancerLocator, a method that
simultaneously infers the proportion and tissue of origin of ctDNA in a
blood sample using WGBS.
CancerLocator performance was evaluated on both simulated data and
real data, and compared to that of 2 established multi-class
classification methods
49. swiftbiosci.com
Publication for Methodology Comparison
NanyangTechnological University, Singapore;UCL
The Accel-NGS Methyl-Seq kit had the
best GC coverage across both genomes
Accel-NGS Methyl-Seq
TruSeq Methyl-Seq
NEBNext Ultra
SPLAT (home brew)
Accel-NGS Methyl-Seq
TruSeq Methyl-Seq
QIAseq Methyl Library kit
50. swiftbiosci.com
Swift Solution for Target Methyl Study
Swift Methyl-Seq + Arbor Bio myBaits MethylCap
+
https://swiftbiosci.com/wp-content/uploads/2020/10/AppNote_Arbor-Swift_MethylSeq_2020-3.pdf
Webinar: https://www.youtube.com/watch?v=iZydUU-DZgI
53. swiftbiosci.com
• Consists of individually synthesized and quality controlled
probes that have been validated to provide the highest level
of performance
• ~9-hour workflow
• 500 ng per library, up to 12-plex
• 150-350 bp fragment size
• Customizable
Swift Hybridization Capture Kits
Accel-Amplicon™ Panels
• Accel-Amplicon and SNAP Panels combine the
easiest, fastest workflow with flexible content to
accelerate your variant discovery and screening.
Simply leverage our pre-designed, validated core
content and add your own targets.
• ~2-hour (Accel)/ ~3-hour (SNAP) workflow
• 10 ng input sample
• Average amplicon size ~130-140bp
• Customizable
Panel size
Gene Panels
(<50genes)
Gene Panels
(>50genes)
DAR
(Disease associate regions)
Exome
20-30%Probes
70-80%Amplicon
50%Probes
50%Amplicon
70-80%Probes
20-30%Amplicon
80-90%Probes
10-20%Amplicons
54. swiftbiosci.com
Swift Amplicon NGS Panels
Format
• Core + customizable gene content
• Single-tube, highly multiplexed assay
• DNA to library in 2 hours for Accel-amplicon
3 hours for SNAP panel workflow
• 10 ng input of cfDNA or FFPE DNA
• Illumina®, Ion Torrent™ for Accel-amplicon
Only Illumina® for SNAP Panels
Performance
• Limit of detection of 1% VAF
• On-target > 90%
• Coverage uniformity > 90%
• Compatible with cfDNA and FFPE
• Supports limited amounts of DNA
• Cost-effective
Accel-amplicon SNAP amplicon
55. swiftbiosci.com
• Low uniformity and lack of coverage
• Multiple primer pools increase the input requirement
• You need large contiguous stretches of DNA in order to make library
• Inflexibility to add primers to increase the size of the panel
• Low library complexity
• Inability to cover entire coding regions
Traditional two-primer strategy
57. swiftbiosci.com
• OVERLAPPING AMPLICONS IN A
SINGLE REACTION
• Low total input
• Few reagents, less time
• Fast workflow
• ~2hrs or 3hrs
• Accel-Amplicon™ or SNAP Amplicon panels
may be used to interrogate the following types
of variants in samples:
- SNV
- Insertions and deletions
- CNV
Why are Swift Amplicon Products Special?
Multiplex PCR with
overlapping target
specific-primers
58. Swift Panel Design base on OncoKB and market
research
Included
OncoKB Introduction
https://www.youtube.com/watch?v=XqoKrrm2Boc&feature=youtu.be
Swift used:
FDA-recognized biomarkers
Standard of care biomarkers
59. Available Panels
56G and 57G Pan-Cancer Profiling
EGFR Pathway (KRAS/NRAS/BRAF)
BRCA1 and BRCA2
BRCA1, BRCA2 and PALB2
TP53 (all exons)
CFTR (all exons, UTRs, some introns)
Sample_ID
Colorectal Cancer
Lynch Syndrome
Myeloid Disease
Lung Cancer
Gene-Based Disease-Based
60. swiftbiosci.com
• ERASE-Seq (Elimination of Recurrent Artifacts and Stochastic Errors) functions by
quantitatively modeling the background error profile of normal controls that have
gone through the library prep and sequencing process in order to establish the
inherent noise distribution for each possible variant
• ERASE-Seq delivers superior detection sensitivity to 0.05% allele frequency (AF),
with a false positive rate 10-100X lower than leading molecular barcode.
Benefits:
• Superior sensitivity and 10-100X fewer false positives than molecular barcodes (UMIs)
• Excels in the 0.05%-0.5% AF range where molecular barcodes struggle
• Any targeted panel can be adapted easily to ERASE-Seq with software validation- and no barcodes needed
• Provides similar detection performance to digital PCR, but can test for thousands of variants per test
• Validated in numerous sequencing labs globally
62. swiftbiosci.com
Swift Amplicon HS – Features, Benefits, Pricing
Features and Benefits
• Sensitive and Specific
Robustly detect SNVs and indels down to 0.2%
• Compatible with cfDNA
Amplifies from 10-20 ng of cfDNA
• Fast workflow, high quality data
From DNA to Illumina® libraries within 3 hours
• Paired Data Analysis Tools
Cloud-based via Genialis or open-source
Ordering Information
Swift Amplicon HS EGFR Panel, Cat. No. HS-51024, 24 rxns
A focused cfDNA-compatible panel covering clinically-relevant oncology
hotspots including EGFR T790, KRAS G12/G13,NRAS Q61 and BRAF V600
64. Using a custom panel targeting 30 hotspot amplicons in
these four genes, NGS was performed on cell-free DNA
extracted from plasma at the time of hysterectomy and the
matching tumor DNA from 48 patients with endometrioid
endometrial carcinomas.
These results demonstrate that mutations in genes
relevant to endometrial cancer can be identified in the
peripheral blood of patients at the time of surgery
65.
66. swiftbiosci.com
Conclusion: ctDNA could be a powerful tool for therapy decisions and patient management in a large number of cancers across a variety of stages.
Summary:
• The data demonstrate that ctDNA can be a
reliable marker of the solid tumor in a large
number of tissue types in non‐metastatic cancers.
• These presurgical ctDNA can serve a surrogate
marker for patient prognosis.
68. swiftbiosci.com
Today’s Topic
Cancer Study
Genomic
Sequencing
RNA
Sequencing
Swift RNA library kit
Swift Rapid RNA library kit
After this training session:
• Able to know benefit of choosing each Swift DNA/ RNA library prep kit for cancer study
• Able to know benefit of Swift amplicon product
Amplicon
Panel
Hyb Capture
Swift DNA library prep kit+
Swift hyb capture panel / 3rd party panel
• Accel-NGS 2S kit
• Accel-NGS 1S kit
• 2S Turbo
• 2S Sonic
DNA
Methylation
WGS
Swift gene/cancer-
based panel
Somatic/germline
mutation detection
Fusion gene
Alternative splicing
RNA expression
Rare & novel transcripts
Disease-associate SNV
…
Hyb Capture WGBS
Swift Methyl-seq Kit+
Arbor Bio myBaits MethylCap
Swift Methyl-seq Kit
Hyb Capture RNA-seq
Swift RNA library kit or
Swift Rapid RNA library kit
+
Swift hyb capture panel / 3rd
party panel
In cancer research each cancer sample presents the researcher with an altered genome that contains a unique and unpredictable number of point mutations, indels, translocations, fusions, and other aberrations.
Turbo is the only swift DNA library prep kit using enzymatic fragment method, because the workflow is simple & fast with robust performance hence it’s suitable for large scale lab as routine use.
The easiest way to differentiate turbo from 2S & 1S is to check with input range..
1S- Aaptase, 2S special workflow, allow down to 10pg
Because tubo use enzyme to fragment DNA samples & cannot separate from master mix, as a reulst, tubo cannot support already fragmentated DNA samples such as short amplicon or cfDNA.
DNA library pre kit for everyday samples & routine use.
1. Flexible & fast robust workflow & adapter choice
2. Wide input range
Two workflow for customer depends on their choice of index, if customer want to choose index directly from swift, that’s the left workflow. Or they want to choose their own full-length adapter, it’s the right workflow. The upfront workflow is the same.
We have validated up too 768-plex CD or 96-plex UDI
Otherwise they can go to other suppliers of adapter such as IDT, KAPA as long as it’s TA ligation & full-length adapter
We also compatible with various type of capture probes brands.
Not compatible with cfDNA
Ligation: ligate truncated ds adapter & finishing library construction by PCR
Automation, hand multiple plate on one time, don’t have on deck chillers
Physical frag method create damaged DNA, no enzyme in traditional polishing mix can tim a damaged 5’ base, cause a substantial fraction of DNA fag. do not get converted into NGS molecules.
Damaged 5’ remain ligation incompatible to NGS adapters
Sequential ligation prevents adapter dimer formation and allows optimized ligation to each strand.
Equivalent efficiency at all inputs, no adapter titration needed.
During Ligation I, the P7 adapter is attached to the repaired 3’ termini.
During Ligation II, the P5 adapter is attached to the repaired 5’ termini.
DNA from FFPE samples is susceptible to substantial damage resulting from the fixation process, leading to cross-linking and fragmentation
Oxidation damage of DNA in FFPE samples also accumulates over time
Accel-NGS kit chemistry can handle both damaged and short DNA fragments
Ideally suited for clinical samples, such as FFPE or plasma
Whole exome sequencing (WES) and targeted sequencing of circulating tumor DNA (ctDNA) allowed us to monitor responses to therapy and to identify and then follow mechanisms of resistance.
how PDXs can be used to validate hypothesis- driven combination therapies for patients with melanoma.
WES of ctDNA could reveal mechanisms of resistance to therapy & make decisions about when to continue and when to withdraw treatment.
resistance emerges in the majority of patients on targeted therapies and not all patients respond to immunotherapies, so it is clinically challenging to select patients for these different modalities, to determine when to switch between modalities and to select second-line therapies for patients who fail to respond or who relapse.
https://www.labpulse.com/index.aspx?sec=sup&sub=onc&pag=dis&ItemID=800034
https://www.christie.nhs.uk/media/3756/legacymedia-4159-final_target_poster_asco_2016_final-draft_25-05-16.pdf
https://www.precisiononcologynews.com/sequencing/liquid-biopsy-utility-reinforced-early-results-uk-target-program#.Xs96KV0RpN0
on a routine basis, with a data turnaround time compatible with clinical practice and at an affordable cost (approximately £1,600 per patient) that leads to benefit in a proportion of phase I trial patients.
The first part of TARGET included 100 patients with 22 different types of solid tumors, the most common of which were colorectal cancer, breast cancer, and non-small cell lung cancer. Participants had received a mean of two prior therapies.
The overall intent of TARGET was to develop a robust work- flow supporting clinical decision-making that can be delivered on a routine basis, with a data turnaround time compatible with clinical practice and at an affordable cost.
Not a swift publication, but worth to mention to the customer who want to use 1S kit for cfDNA short fragment retention
Similar to targeted DNA sequencing for somatic variant detection, analyzing a focused set of RNA sequences allows sequencing to greater depth and supports rapid, cost-effective sample processing. Panels with preselected, expert-defined content are available for several areas of interest.
Ribodepletion Workflow Methods
50-100 ng of UHR and FFPE Samples 1-2 were ribodepleted using Lexogen Ribocop4 V1.3 and eluted in 5 L dH2O for input into the Swift RNA Library Kit5. Swift RNA libraries were made with the following adjustments: fragmentation at 65C for 5 min and a 1.2X post-RT SPRI clean-up (see Protocol Considerations below). All libraries were amplified using 12 PCR cycles. Libraries were sequenced on a Miniseq 2 x 75 bp and downsampled to 3 million reads prior to analysis with STAR6, picard7, rnaseqc8, and fgbio9. CDS = coding sequence; UTR = untranslated region (5’ and 3’).
Bioanalyzer date 19.10.11
Adaptase step is a highly efficient, template-independent reaction that simultane-ously performs tailing and ligation of truncated adapter to 3’ ends
Extension step is used to incorporate truncated adapter 1 by a primer extension reaction
Ligation step is used to add truncated adapter2 to the top/bottom strand only.
Index PCR increase yield and incorporates full length adapters for single or dual indexing
Size selection must occur before bisulfite conversion because conversion will fragment DNA, affecting fragment size selection. Improper size selection may affect CpG island coverage.
CCGA: This is a prospective, multi-center, observational study with collection of de-identified biospecimens and clinical data from at least 15,000 participants from clinical networks in the United States and Canada. The study will enroll approximately 10,500 cancer participants (CANCER arm) and approximately 4,500 representative participants without a clinical diagnosis of cancer (NON-CANCER arm). Clinical information, demographics, and medical data relevant to cancer status are collected from all participants and their medical record at baseline (time of biospecimen collection), and subsequently from the medical record at intermittent future time points, at least annually for up to 5 years.
The PATHFINDER Study is a prospective, multi-center study that will evaluate the implementation of GRAIL’s multi-cancer early detection test into clinical practice. GRAIL’s test is designed to detect and localize multiple types of cancer through a single blood draw, with a very low false positive rate.
PATHFINDER is the first time GRAIL’s multi-cancer early detection test will be used to return results to healthcare providers and communicated to participants to help guide appropriate diagnostic workup for more than 50 cancer types. The study will enroll approximately 6,200 participants, and they will be followed for 12 months from the time of their enrollment.
The STRIVE Study is a prospective, observational, longitudinal, cohort study that has enrolled approximately 100,000 women at the time of their screening mammogram. STRIVE will be used to validate a blood test for the early detection of multiple cancer types. Participants completed a health questionnaire and provided a blood sample around the time of their screening mammogram and will be followed for up to five years to capture clinical outcome data, including cancer diagnoses.
The SUMMIT Study is a prospective, observational, longitudinal, cohort study being conducted in London in the United Kingdom. It is designed to enroll approximately 50,000 men and women age 50 to 77 years who do not have a cancer diagnosis at the time of enrollment. SUMMIT aims to evaluate a blood test designed to detect multiple types of cancer, including lung cancer. Approximately half the participants will be people at high risk of lung and other cancers due to a significant smoking history, and the other half will be people who are not at high risk for cancer based on smoking history. Participants will be followed annually for three years and then will be followed for five years through national health registries as well as their medical records.
The first sub-study aimed to identify the highest performing assay(s) for further development and included three independent, comprehensive sequencing approaches
A methylation-based assay was selected for further development in this second sub-study based on the previous finding that WGBS outperformed targeted sequencing and WGS approaches targeting SNVs/small insertions and deletions and CNVs, respectively.
This second sub-study reported herein included 4841 participants from CCGA divided into a training set (n = 3133: 1742 cancer and 1391 non-cancer) and an independent validation set (n =1354: 740 cancer and 614 non-cancer);
In summary, cfDNA sequencing of informative methylation patterns detected a broad range of cancer types at metastatic and non-metastatic stages with specificity and sensitivity performance approaching the goal for population-level screening.
CancerLocator:
We propose a probabilistic method, CancerLocator, which exploits the diagnostic potential of cell-free DNA by determining not only the presence but also the location of tumors. CancerLocator simultaneously infers the proportions and the tissue-of-origin of tumor-derived cell-free DNA in a blood sample using genome-wide DNA methylation data. CancerLocator outperforms two established multi-class classification methods on simulations and real data, even with the low proportion of tumor-derived DNA in the cell-free DNA scenarios. CancerLocator also achieves promising results on patient plasma samples with low DNA methylation sequencing coverage.
CancerDector:
The detection of tumor-derived cell-free DNA in plasma is one of the most promising directions in cancer diagnosis. The major challenge in such an approach is how to identify the tiny amount of tumor DNAs out of total cell-free DNAs in blood. Here we propose an ultrasensitive cancer detection method, termed ‘CancerDetector’, using the DNA methylation profiles of cell-free DNAs. The key of our method is to probabilistically model the joint methylation states of multiple adjacent CpG sites on an individ- ual sequencing read, in order to exploit the perva- sive nature of DNA methylation for signal amplifica- tion. Therefore, CancerDetector can sensitively iden- tify a trace amount of tumor cfDNAs in plasma, at the level of individual reads. We evaluated CancerDetec- tor on the simulated data, and showed a high con- cordance of the predicted and true tumor fraction. Testing CancerDetector on real plasma data demon- strated its high sensitivity and specificity in detecting tumor cfDNAs. In addition, the predicted tumor frac- tion showed great consistency with tumor size and survival outcome. Note that all of those testing were performed on sequencing data at low to medium cov- erage (1× to 10×). Therefore, CancerDetector holds
the great potential to detect cancer early and cost- effectively.
A panel can design all bases across the gene or can be focused on specific mutation hotspot. Since genes design relies on tilling overlapping amplicons, if ampliseq want to amplify whole sequence of a gene, regions A &C can be pooled together, but not for region B. As a result, overlapping primers must be separated in different PCR reactions. A mutation hotspot design typically result in un-overlapping amplicons, primers can combined into single-multiplex reaction.
Using OncoKB (oncokb.org), we’ve developed a set of targets for each cancer subtype that are FDA-recognized biomarkers predictive of response to FDA-approved drugs or standard of care biomarkers predicative of response to an FDA-approved drug.
In addition, we have completed market research on existing cancer specific panels to guide our development of a list of core targets.
The Accel-Amplicon 56G Oncology Panel v2 offers comprehensive and hotspot coverage of 56 clinically-relevant oncology-related genes. This panel utilizes a 263-amplicon design, covering over 16,000 COSMIC mutations, to generate targeted libraries compatible with Illumina sequencing platforms and now includes 104 exonic and gender Sample_ID amplicons spiked in at a low percentage (2-4% of reads) for tracking tumor-normal pairs and samples in longitudinal studies.
For analysis we have VarSome as you said but also a partnership with Fluxion Biosciences, which allows achieving <1% frequency variant calling from cfDNA using a published error subtraction statistical model called ERASE-seq (PCR and sequencing errors are random, but low frequency variants are real and persist in replicate samples). Fluxion is a great partner of ours and willing to do free proof of concept demos and provide low per sample analysis software. Or we can share with any customer our open source Linux pipeline for free at any time via Docker image / FTP
Unique molecular identifier incorporated into PCR product during first 3 cycles
Noise removal reveals true positive variant calls at 0.2% - 1.0% frequency
From 10-20 ng DNA to Illumina® library in < 3 hrs
> 95% on-target and coverage uniformity from human cfDNA and synthetic cfDNA controls
Maximum10-100 amplicons/tube